AMP PD consolidates data from eight unified cohorts: BioFIND, Harvard Biomarkers Study (HBS), Lewy body dementia case-control cohort (LBD), LRRK2 Cohort Consortium (LCC), Parkinson’s disease Biomarkers Program (PDBP), Parkinson’s Progression Markers Initiative (PPMI), Study of Isradipine as a Disease-modifying Agent in Subjects With Early Parkinson Disease, Phase 3 (STEADY-PD3), and the Study of Urate Elevation in Parkinson’s Disease, Phase 3 (SURE-PD3). This evidence concerns the gene LRRK2 and Parkinson disease.